ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 8, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	1,421	854	898	-	-	-
Market Cap Growth	101.26%	-4.88%	-	-	-	-
Enterprise Value	1,095	541.32	679.1	0	0	0
Last Close Price	30.50	20.12	26.64	-	-	-
PB Ratio	4.27	2.78	3.49	-	-	-
P/TBV Ratio	3.88	2.52	3.25	-	-	-
Debt / Equity Ratio	0.00	0	0.00	0.00	0.00	-
Net Debt / Equity Ratio	-1.01	-1.02	-0.85	0.98	1.92	-
Net Debt / EBITDA Ratio	2.08	1.76	2.32	2.01	4.42	-
Net Debt / FCF Ratio	2.42	1.95	3.12	2.69	3.74	-
Quick Ratio	13.06	12.06	12.67	12.94	19.54	-
Current Ratio	13.95	12.83	13.14	13.76	21.84	-
Return on Equity (ROE)	-46.02%	-58.88%	-39.36%	-64.18%	-113.98%	-
Return on Assets (ROA)	-45.97%	-58.39%	-43.06%	-43.12%	-40.37%	-
Return on Invested Capital (ROIC)	-32014.90%	-733.45%	-366.99%	-1028.90%	-657.33%	-
Return on Capital Employed (ROCE)	-49.68%	-62.86%	-46.10%	-45.77%	-42.31%	-
Buyback Yield / Dilution	-22.48%	-22.22%	-1369.88%	-67.64%	50.71%	-
Total Shareholder Return	-22.48%	-22.22%	-1369.88%	-67.64%	50.71%	-

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 11, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 8, 2026

Data Sources Report a data error